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Breast cancer is the most common form of cancer in women in the western world, and in spite 
of some decline in death rates in recent years it is still the second most common cause of 
death from cancer, in women (1).  
For more than three decades, the estrogen receptor (ER) has been the most important 
biomarker of breast cancer, largely due to the substantial benefit that endocrine therapy 
provides in the treatment of ER positive tumors, in women of all ages (2). Endocrine therapies 
currently available include selective estrogen receptor modulators (SERMs), like tamoxifen 
and raloxifene (3). Raloxifene acts as an estrogen antagonist in the breast by competitive 
binding to the ER, inhibiting estrogen-induced breast tissue proliferation and preventing the 
growth of mammary tumors. In addition, it shows no increase in incidence of endometrial 
cancer, which is an advantage compared to tamoxifen (4). The successes of these endocrine 
therapies, however, are often limited. So, it is important to continue searching for new 
strategies and/or drugs that overcome resistance problems and that can be potent enough 
with fewer adverse effects.    
In this work, we studied the effect of two new synthetic di(hetero)arylamines, named MJQ2 
and MJQ3 (which have in common with raloxifene a benzothiophene ring), in cell proliferation 
and apoptosis of two different cell lines from breast cancer: MCF-7 (ER positive) and MDA-
MB-231 (ER
 
negative).  
Our results showed that both diarylamines induce apoptosis without significant necrosis 
(evaluated by Hoechst-PI staining), at the IC50 concentration that inhibits cell proliferation 
(evaluated by the SRB assay). The results obtained with TMRM, a marker of mitochondrial 
membrane potential, suggest that mitochondrial disruption can be involved in this apoptotic 
process. These effects are more pronounced in the MCF-7 cell line (ER positive), suggesting 
that the presence of the ER might be important in the response to these compounds. 
Confirmation of their interaction with the ER was obtained in the E-Screen assay, where a 
clear antagonism of the proliferative effects of the hormone 17β-estradiol was observed with 
both compounds, at non-toxic concentrations.  
The overall results suggest that these new synthetic “raloxifene-like” drugs might have 
potential to be further developed as alternative hormonal or adjuvant therapies for breast 
cancer.  
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